Progression in characterizing the symptoms and treatments for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent development of coronavirus disease 2019 (COVID-19).
The Infectious Disease Society of America has issued guidelines to aid in the treatment and management of patients with COVID-19.
As infections with SARS-CoV-2 continue to increase, there has been a concurrent increase in news and data, both accurate and inaccurate.
The Centers for Disease Control and Prevention has issued an official health update for the outbreak of novel coronavirus 2019-nCoV.
Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
Approximately 1 in 5 people with HIV also has prevalent DM, and control of hemoglobin A1c levels in these patients may have a beneficial effect on CD4 counts.
